uniQure N.V. has made a significant advancement in its efforts to treat Huntington's disease. The U.S. Food and Drug Administration (FDA) has accepted for review the company's Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy. This acceptance is particularly noteworthy as it comes under the Accelerated Approval pathway, which could expedite the availability of this treatment for patients. The FDA has also granted Priority Review status to the application, setting a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027.

The acceptance of this BLA is a crucial milestone for uniQure, as it seeks to provide a much-needed treatment option for Huntington's disease, a condition that has long lacked effective therapies. According to Matt Kapusta, the CEO of uniQure, the company believes that ifezuntirgene inilparvovec could potentially become the first disease-modifying treatment for this devastating condition. The company is committed to working closely with the FDA, clinicians, and the Huntington's community throughout the review process.

Background

uniQure N.V. is a leading gene therapy company based in Amsterdam, Netherlands, specializing in transformative therapies for patients with serious medical needs. The company operates under the SIC classification of Pharmaceutical Preparations (SIC 2834) and trades on the Nasdaq under the ticker symbol QURE. Recent filings include an 8-K on November 2, 2026, which details the FDA's acceptance of the BLA for ifezuntirgene inilparvovec.

What the Filing Says

The filing confirms that the FDA has accepted for review the BLA for ifezuntirgene inilparvovec, stating that the application has been granted Priority Review. The FDA plans to discuss the application at an upcoming Advisory Committee meeting, with the company set to begin patient screening for the confirmatory trial by the end of 2026.

Impact

This development may significantly affect patients suffering from Huntington's disease by potentially providing a new treatment option. The acceptance of the BLA also places uniQure in a competitive position within the pharmaceutical preparations industry, where other companies are also exploring treatments for neurological conditions.

What's Next

The next steps involve the FDA's review process, with the company awaiting a date for the Advisory Committee meeting. The filing does not specify any further actions beyond the review process.